Sclerotic skin response and change in corticosteroid doses over time in pediatric patients. (A) Sclerodermatous cGVHD of the skin in a pediatric patient (patient 16) at baseline and after 8 weeks and 6 months of low-dose IL-2 therapy. There was complete resolution of sclerotic skin by 6 months, although residual hyperpigmentation of the skin remained. Patient 1 (not shown) also had a similar skin response. (B) Change in daily corticosteroid doses (mg/kg) for pediatric patients at baseline, 6 months (6MO), and 1 year (1Y) of IL-2 therapy. Each line represents an individual patient over time.